Insulet signs international distribution agreement for OmniPod

Insulet and Ypsomed Sign International Distribution Agreement for the OmniPod Insulin Management System

People with diabetes in certain European countries, Australia and China to have access to Insulet’s innovative, tubeless insulin pump for the first time

BEDFORD, Mass. and BURGDORF, Switzerland, Jan 05, 2010 /PRNewswire-FirstCall via COMTEX/ – Insulet Corporation (Nasdaq: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, and Ypsomed AG (SIX Swiss Exchange: YPSN), a leading independent diabetes specialist and technology provider of innovative injection systems for self-medication in Europe, today announced an exclusive agreement for the distribution of the OmniPod Insulin Management System in nine countries across Europe, as well as China and Australia.
Ypsomed has been a leader in the diabetes industry for over 25 years. The company developed the Disetronic Insulin Pump, which it sold to Roche Holdings AG in March 2003. After the sale, Ypsomed retained its European distribution network and today is a leading distributor of insulin pumps, blood glucose meters and diabetes care supplies. In Germany, Ypsomed has a 40% market share of insulin pump users and access to more than 80% of the insulin pumpers in the country.

Read more here: